339 related articles for article (PubMed ID: 27966034)
21. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
[TBL] [Abstract][Full Text] [Related]
22. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
Ohata Y; Tomita Y; Nakayama M; Tamura K; Tanigawara Y
J Infect Chemother; 2011 Dec; 17(6):831-41. PubMed ID: 21773752
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
24. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
[TBL] [Abstract][Full Text] [Related]
26. Maximally effective dosing regimens of meropenem in patients with septic shock.
Sjövall F; Alobaid AS; Wallis SC; Perner A; Lipman J; Roberts JA
J Antimicrob Chemother; 2018 Jan; 73(1):191-198. PubMed ID: 28961812
[TBL] [Abstract][Full Text] [Related]
27. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
28. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
[TBL] [Abstract][Full Text] [Related]
29. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
31. A meropenem pharmacokinetics model in patients with haematological malignancies.
Contejean A; Jaffrelot L; Benaboud S; Tréluyer JM; Grignano E; Willems L; Gauzit R; Bouscary D; Gana I; Boujaafar S; Kernéis S; Hirt D
J Antimicrob Chemother; 2020 Oct; 75(10):2960-2968. PubMed ID: 32737508
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
34. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
[TBL] [Abstract][Full Text] [Related]
35. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
Minichmayr IK; Roberts JA; Frey OR; Roehr AC; Kloft C; Brinkmann A
J Antimicrob Chemother; 2018 May; 73(5):1330-1339. PubMed ID: 29425283
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of meropenem among post-operative patients in Pakistan.
Zaman M; Khan HM; Usman M; Khokhar MI; Rasheed H; Abbas M; Khan RR; Saleem R
Int J Clin Pharmacol Ther; 2021 May; 59(5):398-408. PubMed ID: 33480841
[TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
39. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
[TBL] [Abstract][Full Text] [Related]
40. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
